January 28, 2026
Nexsen (ASX:NXN) expands GBS diagnostic platform into neonatal care with $500,000 AEA Ignite grant
Nexsen (ASX:NXN) has secured $500,000 in non-dilutive Federal funding to extend its rapid Group B Streptococcus diagnostic technology from maternal screening into neonatal testing.